van Herwaarden Joost A, van de Pavoordt Eric D W M, Waasdorp Evert J, Albert Vos Jan, Overtoom Tim ThC, Kelder Johannes C, Moll Frans L, de Vries Jean-Paul P M
Department of Vascular Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands.
J Endovasc Ther. 2007 Jun;14(3):307-17. doi: 10.1583/06-1993.1.
To evaluate the long-term single-center results with the AneuRx stent-graft in endovascular abdominal aortic aneurysm (AAA) repair (EVAR).
Between December 1996 and August 2003, 212 patients (197 men; mean age 71.3+/-7.0 years) were treated with the AneuRx stent-graft for an infrarenal AAA. Postoperatively, patients were enrolled in a fixed surveillance protocol, and data were prospectively captured into a database.
Graft deployment was successful in 98.6% (209/212). Thirty-day mortality was 2.4%. Median hospital stay was 4.3+/-5.5 days. Median follow-up was 52.0 months (range 1-109); only 1 patient was lost to follow-up. At 9 years, patient survival was 56% and freedom from secondary interventions was 48%. In 68% of cases, these reinterventions were needed for a fixation-related complication, and most of these complications (75%) encompassed the area of the proximal aneurysm neck. Primary clinical success was 37% at 9 years. After secondary interventions, the assisted primary clinical success improved to 73% at 9 years. Freedom from aneurysm-related death was 97% at 1 year and 90% at 9 years.
As an alternative to open repair, EVAR with the AneuRx device has low perioperative mortality. Reinterventions are mostly due to fixation-related complications. While the overall mortality risk in this population was 5% per year, annual aneurysm-related death was only 1%. The focus should be on surveillance and reducing the rate of long-term complications, which might be possible with improved proximal stent-graft fixation.
评估AneuRx覆膜支架在血管腔内修复腹主动脉瘤(AAA)中的单中心长期疗效。
1996年12月至2003年8月期间,212例患者(197例男性;平均年龄71.3±7.0岁)接受了AneuRx覆膜支架治疗肾下腹主动脉瘤。术后,患者进入固定的监测方案,并将数据前瞻性地录入数据库。
支架植入成功率为98.6%(209/212)。30天死亡率为2.4%。中位住院时间为4.3±5.5天。中位随访时间为52.0个月(范围1-109个月);仅1例患者失访。9年时,患者生存率为56%,无需二次干预的比例为48%。在68%的病例中,这些二次干预是由于固定相关并发症,且大多数此类并发症(75%)累及近端动脉瘤颈部区域。9年时的主要临床成功率为37%。二次干预后,辅助主要临床成功率在9年时提高至73%。1年时无动脉瘤相关死亡的比例为97%,9年时为90%。
作为开放修复的替代方法,使用AneuRx装置进行血管腔内修复腹主动脉瘤围手术期死亡率较低。二次干预主要是由于固定相关并发症。虽然该人群的总体死亡风险为每年5%,但每年动脉瘤相关死亡仅为1%。重点应放在监测和降低长期并发症发生率上,这可能通过改进近端覆膜支架固定来实现。